Keyword: Tobira Therapeutics

Allergan buys another NASH biotech in M&A spree

Within the same day that Allergan announced a $1.7 billion buyout of tiny NASH biotech Tobira, the Botox maker announced it had bought yet another fatty liver disease company, although for far less and for a much earlier stage candidate.